[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345380-105":59,"doc-detail-345380-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","elucidating-the-binding-and-metabolic-interactions-of-sunitinib-and-sorafenib-with-cytochrome-p450s-cyp2u1-and-cyp2d6","Elucidating the binding and metabolic interactions of sunitinib and sorafenib with Cytochrome P450s CYP2U1 and CYP2D6","","Cytochrome P450 2U1 (CYP2U1) is an extrahepatic monooxygenase that metabolizes endogenous fatty acids and xenobiotic substrates, with high expression in healthy and cancerous thymus tissues. This study examined CYP2U1- and CYP2D6-mediated biotransformation of the thymus tumor-targeting tyrosine kinase inhibitors sorafenib and sunitinib using CYP nanodiscs. LC-MS metabolite profiling showed oxidation of sorafenib to sorafenib N-oxide by both enzymes and dealkylation of sunitinib to N-desethyl sunitinib. Spectroscopy supported favorable binding, and molecular dynamics identified key active-site interactions. Targeted metabolomics quantified metabolite formation, while ELISA and HepG2 migration assays assessed kinase inhibition; sorafenib N-oxide was about twice as potent as parent sorafenib, whereas N-desethyl sunitinib showed limited inhibition, suggesting CYP2U1-local metabolism can modulate antitumor efficacy at thymic sites.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/elucidating-the-binding-and-metabolic-interactions-of-sunitinib-and-sorafenib-with-cytochrome-p450s-cyp2u1-and-cyp2d6/345380/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/elucidating-the-binding-and-metabolic-interactions-of-sunitinib-and-sorafenib-with-cytochrome-p450s-cyp2u1-and-cyp2d6/345380.png","ImageObject",300,407,{"name":92,"@type":93},"Ezra","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-02","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",11,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What enzymes and inhibitors were studied?","Question",{"text":113,"@type":114},"The study investigated CYP2U1 and CYP2D6 and their metabolism of the tyrosine kinase inhibitors sorafenib and sunitinib in nanodiscs.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How were sorafenib and sunitinib metabolized?",{"text":118,"@type":114},"Both CYP2U1 and CYP2D6 oxidized sorafenib to form sorafenib N-oxide. Both enzymes also catalyzed dealkylation of sunitinib to generate N-desethyl sunitinib.",{"name":120,"@type":111,"acceptedAnswer":121},"How did the metabolites affect antitumor activity in cells?",{"text":122,"@type":114},"In HepG2 cellular migration assays, sorafenib N-oxide showed inhibitory effects similar to sorafenib but was about twice as potent as the parent compound. N-desethyl sunitinib showed a much less pronounced inhibition.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},345380,1790441480,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},1099514068035,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Molecular Pharmacology 108 (2026) 100114  \njournal  \nMolecular Pharmacology  \n[homepage:](homepage: www . mo lpharm. as petjournals. org)[ www . mo lpharm. as petjournals. org](homepage: www . mo lpharm. as petjournals. org)  \nARTICLE  \nElucidating the binding and metabolic interactions of sunitinib and sorafenib with Cytochrome P450s CYP2U1 and CYP2D6   \nTiffany Y.-C. Tang 1 , Yupeng Li 2 , Peter Chapman 1 , Emad Tajkhorshid 2 , Aditi Das 1, *  \n1 School of Chemistry and Biochemistry, College of Sciences, Parker H. Petit Institute for Bioengineering and Biosciences, Georgia Institute of Technology, Atlanta, Georgia  \n2 Theoretical and Computational Biophysics Group, NIH Resource for Macromolecular Modeling and Visualization, Department of Biochemistry, and Center for Biophysics and Quantitative Biology, Beckman Institute for Advanced Science and Technology, University of Illinois Urbana-Champaign, Urbana, Illinois  \na r t i c l e i n f o  \nArticle history:  \nReceived 6 October 2025  \nAccepted 16 February 2026  \nAvailable online 24 February 2026  \nKey words:  \nThymus cancer Cytochrome P450 2U1  \nCytochrome P450 2D6 Drug metabolism Tyrosine kinase inhibition  \na b s t r a c t  \nCytochrome P450 2U1 (CYP2U1) is an extrahepatic monooxygenase that metabolizes both endogenous fatty acids and xenobiotic substrates. Because of its high expression in both healthy and cancerous thymus tissues, this study investigated CYP2U1-mediated biotransformation of 2 tumor-targeting tyrosine kinase inhibitors, sorafenib and sunitinib, both are commonly prescribed for thymus cancers. Recombinantly expressed CYP2U1 and CYP2D6 were incorporated into nanodiscs, and their metabolism of sorafenib and sunitinib was investigated. Liquid chromatography—tandem mass spectrometry metabolite profiling revealed that both CYP2U1 and CYP2D6 nanodiscs oxidized sorafenib to generate sorafenib N-oxide and both enzymes catalyzed the dealkylation of sunitinib to form N-desethyl sunitinib. Spectroscopic studies (UV-Visible and fluorescence) confirmed favorable binding interactions of CYP2U1 and CYP2D6 to both drugs tested. Molecular dynamics simulations demonstrated binding of sorafenib and sunitinib in the CYP2U1 active site and identified key interactions between the drug and key residues at the enzyme’s active site. Rates of metabolite formation were quantified by targeted metabolomics, and inhibition of tyrosine kinase was assessed by ELISA assay. Both the parent compound sorafenib and metabolite sorafenib N-oxide showed similar inhibitory effects on cellular migration in HepG2 cells. The metabolite sorafenib N-oxide was approximately twice as potent as the parent compound in inhibiting cancer cell migration. In contrast, N-desethyl sunitinib failed to show similar extent of inhibition. Together, these findings highlight the potential role of extrahepatic CYP2U1 in the local metabolism of tyrosine kinase inhibitors and suggest that CYP2U1-mediated transformations directly influence antitumor efficacy at thymic tumor sites.  \nSignificance Statement: Understanding the interactions between cytochrome P450 2U1 and cytochrome P450 2D6 in nanodiscs and thymus tumor-targeting drugs, sorafenib and sunitinib, led to discovery of new bioactive metabolites that carry differential anticancer properties compared with their parent compounds.  \n© 2026 The Authors. Published by Elsevier Inc. on behalf of American Society for Pharmacology and Experimental Therapeutics. This is an open access article under the CC BY-NC-ND license ([http://](http://)[ ](http://)[creativecommons.org/licenses/by-nc-nd/4.0/](creativecommons.org/licenses/by-nc-nd/4.0/)).  \n1. Introduction  \n* Address correspondence to: Aditi Das, School of Chemistry and Biochemistry, College of Sciences, Parker H. Petit Institute for Bioengineering and Biosciences, Georgia Institute of Technology (GaTech), Atlanta, Georgia 30332, USA. E-mail:  \n[aditi.das@chemistry.gatech.edu](aditi.das@chemistry.gatech.edu)  \n This artic","cbCaiqYO8qwQUlwv","https://ap.wps.com/l/cbCaiqYO8qwQUlwv","pdf",8809803,15,"English","# Introduction\n## Cytochrome P450s and extrahepatic CYP2U1 background\n## CYP2U1-mediated metabolism of endogenous and xenobiotic substrates\n## Study rationale for sorafenib and sunitinib","[{\"question\":\"What enzymes and inhibitors were studied?\",\"answer\":\"The study investigated CYP2U1 and CYP2D6 and their metabolism of the tyrosine kinase inhibitors sorafenib and sunitinib in nanodiscs.\"},{\"question\":\"How were sorafenib and sunitinib metabolized?\",\"answer\":\"Both CYP2U1 and CYP2D6 oxidized sorafenib to form sorafenib N-oxide. Both enzymes also catalyzed dealkylation of sunitinib to generate N-desethyl sunitinib.\"},{\"question\":\"How did the metabolites affect antitumor activity in cells?\",\"answer\":\"In HepG2 cellular migration assays, sorafenib N-oxide showed inhibitory effects similar to sorafenib but was about twice as potent as the parent compound. N-desethyl sunitinib showed a much less pronounced inhibition.\"}]","Elucidating the binding and metabolic interactions of sunitinib and sorafenib with Cytochrome P450s CYP2U1 and CYP2D6 | PDF",1790057481,38,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/961a27110556b6f8874f525d402726d3.webp",983,1315,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b98cd549b4ee1d30ce4a370b606f4969.webp",982,1314,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4bccda320d7f34755e12832271ea7f57.webp",981,1312,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d111b6ce0e60363a5300dd4d6e9b6289.webp",980,1311]